Ascletis Pharma Inc. (ASCLF)
OTCMKTS
· Delayed Price · Currency is USD
0.9325
+0.0394 (4.41%)
At close: May 30, 2025
Ascletis Pharma Employees
Ascletis Pharma had 231 employees as of December 31, 2024. The number of employees increased by 12 or 5.48% compared to the previous year.
Employees
231
Change (1Y)
12
Growth (1Y)
5.48%
Revenue / Employee
$761
Profits / Employee
-$178,481
Market Cap
1.18B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Elite Pharmaceuticals | 64 |
Tian'an Technology Group | 8 |
American Oncology Network | 1,914 |
Glass House Brands | 374 |
CytoDyn | 9 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 116 |
Ascletis Pharma News
- 3 days ago - Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis - PRNewsWire
- 12 days ago - Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA) - PRNewsWire
- 17 days ago - Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints - PRNewsWire
- 4 weeks ago - Ascletis Announces U.S. FDA Clearance of IND Application for Its Oral Small Molecule IL-17 Inhibitor, ASC50, for the Treatment of Psoriasis - PRNewsWire
- 4 weeks ago - Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity - PRNewsWire
- 6 weeks ago - Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity - PRNewsWire
- 2 months ago - Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA - PRNewsWire
- 2 months ago - Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist - PRNewsWire